Hims & Hers Health
Live price unavailable. Yahoo unofficial endpoint may be throttling or the ticker may be misconfigured.
loading 1-year chart…
1-year close · Yahoo Finance · daily interval
What they do in peptide space
Hims & Hers Health is the largest direct-to-consumer telehealth platform delivering compounded peptide therapies in the United States. The company's 2024 launch of compounded GLP-1 access at sub-$200/month pricing meaningfully expanded patient access during the FDA shortage period and positioned HIMS as both a beneficiary and a regulatory-policy target.
The core HIMS proposition is that a licensed physician + 503A compounding pharmacy + DTC distribution can deliver peptide-class therapies at a fraction of the branded retail price. The trade-off is regulatory exposure: the May 2026 FDA proposal to exclude semaglutide and tirzepatide from the 503B bulks list specifically threatens part of the supply chain HIMS depends on.
HIMS also distributes compounded testosterone, finasteride, sildenafil, and a growing portfolio of dermatology peptides. Their public roadmap includes preventative-care telehealth and primary-care expansion — the GLP-1 distribution business is a wedge, not the destination.
Recent mentions
Coming soon — no editorial coverage or FDA alert mentioning Hims & Hers Health in our index yet. Items will surface here as the news / FDA cron pipelines ingest them.